Advertisement
Singapore markets closed
  • Straits Times Index

    3,297.55
    -26.98 (-0.81%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • Dow

    38,589.16
    -57.94 (-0.15%)
     
  • Nasdaq

    17,688.88
    +21.28 (+0.12%)
     
  • Bitcoin USD

    66,620.58
    +383.76 (+0.58%)
     
  • CMC Crypto 200

    1,386.92
    -30.95 (-2.18%)
     
  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     
  • Gold

    2,342.50
    -6.60 (-0.28%)
     
  • Crude Oil

    78.37
    -0.08 (-0.10%)
     
  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     
  • Nikkei

    38,814.56
    +94.06 (+0.24%)
     
  • Hang Seng

    17,941.78
    -170.82 (-0.94%)
     
  • FTSE Bursa Malaysia

    1,607.32
    -2.85 (-0.18%)
     
  • Jakarta Composite Index

    6,734.83
    -96.73 (-1.42%)
     
  • PSE Index

    6,383.70
    -7.13 (-0.11%)
     

Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)

SAN DIEGO, May 14, 2024--(BUSINESS WIRE)--Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company (the "Company"), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days.

About Cue

Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that empowers healthcare providers to streamline their ability to deliver value-based care with fast, highly accurate test results on demand. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive this FDA approval. Cue also received Emergency Use Authorization from the FDA for its molecular Mpox test at the point-of-care. Cue, founded in 2010, holds over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513451572/en/

Contacts

Investor Relations
ir@cuehealth.com

Press
Cue Health
press@cuehealth.com